The four dengue virus serotypes (DENV-1-4) cause the most prevalent mosquito-borne viral 19 disease of humans worldwide. DENV-2 Asian 1 (A1) genotype viruses replaced the Asian-20
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higher viremia than AA-infected patients, although no significant difference in replication in 84 mosquito cells or mosquito infectivity was noted [13] . We sought to investigate the possible role 85 of pre-existing immunity in driving the genotype replacement and subsequent evolution of the 86 A1 lineage. 87
Here, we describe the unusual observation of a naturally occurring substitution in the E 88 protein of successful DENV-2 A1 lineages that appears to confer an antigenic fitness cost. 89
During the replacement of the AA by the A1 genotype in Vietnam and Cambodia, three separate 90 lineages arose almost simultaneously with substitutions at E position 160 (two with K160M and 91 one with K160Q). We explored the possible role of pre-existing immunity on selection of these 92 viruses by testing polyclonal sera against RVPs representing the previously circulating AA as 93 well as three A1 E-160 variants. Surprisingly, A1-160Q and A1-160M RVPs were better 94 neutralized by polyclonal sera in vitro than A1-160K and AA RVPs. Despite this apparent fitness 95 disadvantage, we found that lineages with 160Q and 160M increased in prevalence in both 96 countries over time and achieved higher viremia in patients than lineages with A1-160K. 97 98 METHODS 99
Cloning of RVPs structural plasmids 100
RVPs were produced as previously reported [35] . One plasmid encodes the West Nile Virus 101 (WNV) non-structural proteins (NS1-NS5) with a green fluorescent protein (GFP) reporter 102 protein substituting the structural proteins (provided by T.C. Pierson, NIH), and the second 103 plasmid encodes the DENV structural C-prM-E proteins. Structural genes of the DENV-2 104 reference strain 16681 were first cloned into a pcDNA3.1/V5-His-TOPO vector (provided by 105 T.C. Pierson) and served as a cloning intermediate. Substitutions were then made in the 16681 C-106 prM-E plasmid using the QuikChange Site-Directed Mutagenesis kit (Stratagene) to construct 107 the AA genotype and A1 genotype variants A1-160K, A1-160Q, and A1-160M (Table 1) . 108 109
Generation of RVPs 110
To produce RVPs, 4x10 5 cells were plated per well of a 6-well plate and incubated overnight at 111 37°C in high-glucose DMEM medium supplemented with 10% Fetal Bovine Serum (FBS; 112 Gibco) and penicillin/streptomycin solution (Gibco). The WNV reporter replicon (1µg), the 113 DENV C-prM-E plasmid (3µg), and MIRUS TransIT-LT1 Transfection Reagent (12µl) were 114 transfected into 293T cells according to the manufacturer's protocol and incubated for 4 hours 115 (h) at 37°C. The medium was then changed to low-glucose DMEM medium supplemented with 116 10% FBS and penicillin/streptomycin and incubated for 20h at 37°C and 48h at 28°C. The RVP-117 containing supernatant was harvested and frozen at -80°C. Diseases (HTD) in Ho Chi Minh City approved the use of these anonymized, pre-collected 129
Neutralization assay 145
RVPs were diluted in RPMI complete medium (pH 8.0). RVP neutralization assays were 146 performed as previously described using serial 3-fold dilutions of sera/plasma [38] . Infection of 147 cells was quantified after 48h by measuring GFP-positive cells via flow cytometry and analyzed 148 using FlowJo software. Raw data were graphed as percent infection versus the log of the 149 reciprocal serum dilution, and a sigmoidal dose response curve with a variable slope was 150 generated using GraphPad Prism 5.0 to determine the antibody dilution at which a 50% reduction 151 in infection was observed compared to the no-antibody control (NT50) [38, 40] . Stringent QC 152 rules, including ensuring that viral particles were neutralized according to the law of mass action, 153 the absolute sum of squares was <0.2, and the coefficient of determination (R 2 ) of the non-linear 154 regression was >0.9, were used to ensure reproducibility of results. We hypothesized that the A1 genotype may have succeeded in replacing the AA genotype by 174 acquiring substitutions that allowed it to better escape population immunity. We first generated 9 RVPs representing AA and A1 to analyze their neutralization profiles with population-level 176 patient sera collected in Vietnam before and after the AA/A1 genotype replacement. Starting 177 with A1 DENV-2 reference strain 16681, we used site-directed mutagenesis to introduce amino 178 acid substitutions to generate the consensus of either the A1 or AA genotype, which differ at 179 thirteen amino acids in E ( Table 1) . We initially constructed an A1 RVP with Q at position 160 180 (A1-160Q), as it was a major variant in 2006 when AA was almost fully replaced by A1 in 181
Vietnam. We infected human Raji-DC-SIGN cells with A1-160Q and AA RVPs in the presence 182 of two sets of Vietnamese plasma samples: 25 samples collected in 1997-98, prior to the A1/AA 183 lineage replacement, and 27 samples collected in 2006-07, after the lineage replacement. Both 184 sets were from tetanus patients with unknown prior DENV immune history. 185 DENV neutralization assays can vary from laboratory to laboratory [42] ; here, we used a 186 flow cytometry-based system with human cells, implemented with stringent quality control 187 measures to ensure reproducibility [38] . As expected, AA RVPs were better neutralized by 188
Vietnamese sera collected after the major DENV-2 epidemic (2006-07) than before , 189
suggesting that years of intense AA transmission increased the magnitude of the neutralizing 190 antibody response against the AA genotype ( Figure 1A) . No significant difference in NT50 titers 191 was observed when A1-160Q RVPs were tested with 2006-07 compared with 1997-98 192 Vietnamese patient sera ( Figure 1B) . However, when we compared the neutralization titers of 193 the A1-160Q relative to the AA RVPs, we found A1-160Q RVPs were better neutralized by both 194 the pre-( Figure 1C Post-primary DENV-2 AA infection sera neutralize A1-160Q and AA equally, but post-199 secondary DENV-2 AA sera neutralize A1-160Q better than AA 200
We further probed the difference between A1 and AA DENV-2 genotypes by titrating the RVPs 201 against a panel of sera from the Nicaraguan Pediatric Dengue Cohort Study, which has been 202 ongoing for 12 years and provides continuous monitoring of all DENV infections that occur in 203 the cohort [43, 44] . This allows for identification of the infecting DENV serotype in primary as 204 well as secondary infections [38] . Coincidentally, all DENV-2 viruses circulating in the 205 Nicaraguan cohort were AA genotype, enabling us to test the role of primary AA and secondary 206 AA immunity against the A1 and AA lineages. With primary DENV-2 sera, we did not observe 207 significant differences between neutralization of genotypes A1-160Q and AA (Figure 2A) . 208
However, post-secondary DENV-2 infection sera better neutralized A1-160Q compared to AA 209
RVPs (Figure 2B) . This unexpected observation suggested that A1-160Q viruses may be better 210 neutralized by serotype cross-reactive antibodies. 211
212
Changes in prevalence of A1-160K, A1-160Q, and A1-160M following the AA/A1 genotype 213 replacement 214
We estimated the phylogenetic and temporal relationships among all DENV-2 E genes listed as 215 from Vietnam and Cambodia in GenBank and identified two distinct lineages with variation at E-216 160 that arose in Vietnam in 2006: one with A1-160Q and another with A1-160M (Figure 3) . 217
The proportion of A1 isolates with 160Q or M increased until 2008, at which point DENV-1 218 genotype I viruses were the dominant serotype (2007) (2008) (2009) (2010) and no DENV-2 was sequenced 219 from clinical cases, although DENV-2 did circulate at low levels during this period. When dominated in Cambodia, A1-160M was more commonly isolated than A1-160K ( Table 2) . The physiochemical properties of the variants at position 160 differ; the initial lysine (K) is 237 positively charged, while glutamine (Q) is polar uncharged and methionine (M) is hydrophobic. 238 Position 160, located in a valley on the surface of EDI ( Supplementary Figure 2A) , is a contact 239 residue of two potently neutralizing type-specific DENV-1 human antibodies, 1F4 [45] and 240
HM14c10 [46] , and is adjacent to a site shown to substantially alter DENV-1 type-specific 241 immunity [31]. In DENV-3 viruses, position 160 is adjacent to the site of amino acid deletions 242 (E157 and E158 in DENV-1, -2, and -4 are absent in DENV-3). 243
To investigate whether the difference in serotype cross-reactive neutralization by 244 human sera was due to amino acid variation at E-160, we generated A1-160K and A1-160M 245
RVPs and compared their neutralization by Nicaraguan sera from post-primary DENV-1 and 246 post-primary DENV-3 infections, as well as post-secondary DENV-2 infections. Interestingly, 247 the high neutralization titers to A1-160Q RVPs were significantly reduced when the A1-160K 248
RVPs were tested with Nicaraguan cohort sera from post-secondary DENV-2 infections ( Amino acid substitutions may affect antibody binding by directly modifying the corresponding 258 epitope, but they can also affect distant sites by causing a global change to virion structure or 259 affecting the number of epitopes exposed by the virion through "breathing" [47] . To test whether 260 the 160Q and 160M substitutions modified cross-reactive antibody binding by inducing a global 261 change to virion structure, we tested the neutralization profiles of A1-160Q and A1-160K RVPs 262 using a panel of MAbs. We tested MAb 87.1 and E76 (which target the EDIII A strand, a cryptic 263 viral epitope only accessible with viral breathing or global changes to virion structure), E87 264 (which targets the EDIII C-C loop in the lateral ridge), and MAbs E60, 82.11, E28, E18, and 4G2 265 (which target the EDII fusion loop) against A1-160Q and A1-160K RVPs, but did not find 266 significant differences in their NT50 titers (Supplementary Figure 2B) . The target of E76 in the 267 EDIII A strand is a temperature-dependent epitope, but we observed similar E76 neutralization 268 profiles of A1-160Q and A1-160K at two different temperatures (4°C and 23°C) 269 Figure 2C) . These data provide preliminary evidence that the substitution at 270 position 160 does not alter the overall virion structure and suggest that heterologous antibodies 271 sensitive to the 160 substitutions may directly target an epitope that includes position 160. 272 273 Individuals infected with A1-160Q have significantly higher viremia than those infected 274 with A1-160K 275
We hypothesized that Q and M at position 160, rather than K, must have some in vivo fitness 276 advantage to explain their evolutionary success, despite apparently being better neutralized by 277 polyclonal sera. We compared plasma viremia data for 70 Vietnamese adults infected with A1 278 viruses in 2011. Of these, 70% were secondary, 11% primary, and 19% indeterminate DENV 279 infections. Primary and secondary DENV infections were classified as previously described [37] . 280
The majority (67%) were drawn on day 3 of illness, with 24% on day 2 and 8% on day 4. Adults 281 infected with A1-160Q/M were statistically more likely to have secondary immune responses 282 than those infected with A1-160K (83% versus 43%, 2-sample test for equality of proportions 283 with continuity correction, p<0.002). The day of viremia measurement did not differ 284 significantly between groups (0.17 days, p=0.23, two-sided t-test). 285
On average, individuals infected with A1-160Q/M had 4-fold higher viral titers than 286 those infected with A1-160K (A1-160Q/M=8.05 log10(RNA copies/mL), A1-160K=7.42 287 log10(RNA copies/mL), difference in log10(RNA copies/mL)=0.63; p=0.03, as measured by 288 linear regression). The difference in viremia between A1-160Q/M and A1-160K remained 289 significant when controlling for day of illness (difference in log10(RNA copies/mL)=0.59, 290 p<0.05) and only modestly decreased when also controlling for immune status (difference in 291 log10(RNA copies/mL)=0.50, p=0.12). Figure 5 shows the cumulative distributions of viremia 292 titers for those infected with A1-160K compared with A1-160Q/M, along with the raw viremia 293 data. Thus, although A1-160Q and A1-160M were better neutralized by serotype cross-reactive 294 sera in vitro, viruses with these substitutions achieved higher viremia levels in vivo and were 295 more often observed to cause secondary infections, providing a possible explanation for their 296 increasing rate of detection in clinical cases in Vietnam and Cambodia. 297
298

DISCUSSION 299
Here we report a naturally occurring single substitution in E that significantly alters polyclonal 300 neutralization. We observed that A1 DENV-2 lineages circulating in both Cambodia and 301
Vietnam underwent an amino acid substitution at E position 160, making the viruses more 302 susceptible to in vitro polyclonal antibody neutralization, yet more evolutionarily successful. 303
Based on available DENV-2 E gene sequences, three separate lineages, two with 160M and one 304 with 160Q, arose simultaneously in Vietnam and Cambodia in 2006-2007, and in both countries 305 increased in relative rate of isolation over time. Further, individuals infected with A1-160M and 306 A1-160Q viruses had significantly higher early viremia levels than those infected with A1-160K 307 isolates and were more likely to occur in secondary infections. Our findings suggest that A1-308 160Q and A1-160M substitutions confer a fitness advantage, which allows them to overcome the 309 fitness cost of being better neutralized by serotype cross-reactive sera. However, the specific 310 causal mechanisms underlying the evolutionary success of the A1-160M and A1-160Q lineages 311 remain elusive. 312
One scenario is that A1-160Q, and possibly A1-160M, are more successful at replicating 313 in the presence of poorly neutralizing heterotypic antibodies by taking advantage of antibody-314 dependent enhancement. Globally, DENV-2 is more often isolated from secondary infections 315
[48], and based on our findings, it is plausible that A1-160Q and A1-160M replicate better in 316 DENV-immune individuals than A1-160K. An alternate scenario is that the substitution at 317 position 160 results in an intrinsic fitness advantage in humans and possibly mosquitoes, 318
improving viral replication and dissemination independent of pre-existing anti-DENV antibodies 319 [7, 17] . 320
It is possible that another mutation in the genome explains the fitness advantage. We 321 searched for other variants in E, but position 160 was the only highly variable position; the next 322 most variant site, position 201, was 96% conserved. Full genomes are not available for the 70 323 viremic adults we studied. However, for all full-length sequences of Vietnamese DENV-2 Asian 324 1 viruses in GenBank (n=127), E position 160 was the only major variant (>20% variation) in 325 the E gene. Two positions in the NS5 gene (one in the methyltransferase and one in the 326 polymerase) were major variants, but distinct amino acids at these positions did not directly 327 correlate with E-160 variants. 328
In conclusion, the successful emergence and expanded circulation for multiple years in 329
Vietnam and Cambodia of viruses with a substitution in the E protein (K160Q, K160M) that 330 induces increased susceptibility to cross-neutralization calls for an expanded view of the 331 mechanism(s) of selection driving DENV evolution. October 20-22, 2014, Belém, Brazil. 342
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